A systematic review published in Experimental and Clinical Endocrinology & Diabetes reports that evidence for glucagon-like peptide-1 receptor agonists reducing excessive intrapancreatic fat deposition remains unconfirmed, with preclinical work pointing one way and randomized trials failing to agree.

Intrapancreatic fat deposition, also called non-alcoholic fatty pancreas disease, is abnormal fat accumulation in pancreatic tissue, and the review links it to metabolic syndrome, obesity, insulin resistance and type 2 diabetes. Two of the six included studies were preclinical, carried out in diet-induced obesity animal models, which matters because that is where the cleanest signal sits.

What the search turned up

The authors searched PubMed, Scopus and Google Scholar under PRISMA 2020 guidance and found six studies meeting their eligibility criteria: original data, a GLP-1 receptor agonist intervention, and a pancreatic fat outcome. Four were clinical. Several papers that survived to full-text review were demoted to background because they were secondary literature or did not actually test a GLP-1 receptor agonist, which is a more honest piece of bookkeeping than most reviews bother with.

Key results

In the preclinical work, liraglutide and semaglutide attenuated pancreatic endoplasmic reticulum stress, islet-cell apoptosis and lipid dysregulation in obesity models. The human picture is messier: one retrospective study reported a significant reduction in pancreatic fat with liraglutide, while randomized trials of liraglutide, exenatide and dulaglutide did not consistently show a significant between-group reduction. Direct pancreatic fat outcome data for semaglutide in humans are missing entirely.

The class effect question

The review does cite one external counterweight: a 2026 systematic review and meta-analysis of randomized trials across glucose-lowering drug classes reported a significant pooled reduction in intrapancreatic fat deposition with GLP-1 receptor agonists. The authors treat that as independent quantitative support for a class effect, while pushing back on the "dual-purpose" framing, noting these drugs already carry cardiovascular, renal and weight-related metabolic benefits and that pancreatic fat is one facet of that profile rather than a separate mechanism.

Limitations

Samples were small, imaging methods were heterogeneous, and the studies could not separate pancreas-specific effects from reductions in hepatic and visceral fat. The condition itself still lacks standardized diagnostic criteria and is often underdiagnosed.

Bottom line

The authors call the role unconfirmed and ask for prospective powered trials using standardized imaging alongside hepatic and visceral fat measurement before any of this reaches clinical practice. That is the right ask, and the fact that six studies is the entire usable literature tells you how early this is.